N/A
Completed N=3
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
Chronic Kidney Diseases · Type 2 Diabetes
Source: ClinicalTrials.gov NCT02608177 ↗
Enrolled (actual)
3
Serious AEs
0.0%
Results posted
Sep 2018
Primary outcomePrimary: Glucose Time in Range — 495.2; 573.3 minutes per day
Summary
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glucose Time in Range |
495.2; 573.3 | — |
| SECONDARY Glycemic Variability |
40.9; 41.5 | — |
| SECONDARY Hypoglycemia |
4; 2 | — |
| SECONDARY Biomarkers of Systemic Inflammation |
— | — |
| SECONDARY Biomarkers of Oxidative Stress |
— | — |
| SECONDARY Biomarkers of Albuminuria |
— | — |
Eligibility Criteria
Inclusion Criteria
- Type 2 diabetes
- eGFR 15-59 mL/min/1.73 m2
- Hemoglobin A1c 40 kg/m2
- Actively using CGM for clinical care
- End stage renal disease needing dialysis
- Kidney transplant
- Pregnant or nursing
- Unable to provide informed consent
Data sourced from ClinicalTrials.gov (NCT02608177). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.